Lipocine Announces Director Resignation and Shareholder Voting Results

SALT LAKE CITY — Lipocine Inc. (NASDAQ: LPCN) disclosed the departure of director Mahesh Shah from its board effective June 1 2026 according to an 8-K filed with the SEC on June 4 2026.

The filing covers three items: director and officer changes under Item 5.02 submission of matters to a vote of security holders under Item 5.07 and exhibits under Item 9.01. Shah's resignation is listed without a stated cause or immediate replacement named in the document. The company did not report any concurrent changes to its principal executive or financial officers.

WHAT IT CHANGES: Prior to June 1 the board included Shah as one of its directors. Following the effective date the board operates with one fewer member until any replacement is elected or appointed. No new director election appears in the current filing.

The annual meeting covered in Item 5.07 produced voting outcomes on company proposals though specific vote tallies and proposal text are contained in the attached exhibits rather than the body of the form.

WHY IT MATTERS DOWNSTREAM: Board composition directly affects corporate governance and oversight of Lipocine's clinical pipeline including its oral testosterone and lipophilic drug candidates. A reduced board may require the remaining directors to redistribute committee responsibilities until a replacement is named.

Under SEC rules any subsequent appointment of a new director would trigger an additional Form 8-K within four business days. Shareholders who voted at the annual meeting now have ratified or rejected the company's proposals on executive compensation director elections or other matters referenced in the exhibits setting the corporate record for the coming year.

This filing represents the latest board-level change for the micro-cap biotech firm which has previously used 8-K filings to report leadership adjustments tied to its efforts to commercialize therapies for endocrine and metabolic disorders. The company remains subject to Nasdaq continued-listing requirements that include maintaining a minimum number of independent directors.

The complete filing including the exhibits detailing the shareholder vote counts is available on the SEC's EDGAR database under accession number 0001493152-26-027266.